SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.

Détails

Ressource 1Télécharger: BIB_30CF56D747F7.P001.pdf (850.23 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_30CF56D747F7
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.
Périodique
Retina (philadelphia, Pa.)
Auteur(s)
Bousquet E., Beydoun T., Rothschild P.R., Bergin C., Zhao M., Batista R., Brandely M.L., Couraud B., Farman N., Gaudric A., Chast F., Behar-Cohen F.
ISSN
1539-2864 (Electronic)
ISSN-L
0275-004X
Statut éditorial
Publié
Date de publication
12/2015
Peer-reviewed
Oui
Volume
35
Numéro
12
Pages
2505-2515
Langue
anglais
Notes
Publication types: Journal Article ; Randomized Controlled Trial
Publication Status: ppublish
Résumé
PURPOSE: To evaluate the effect of spironolactone, a mineralocorticoid receptor antagonist, for nonresolving central serous chorioretinopathy.
METHODS: This is a prospective, randomized, double-blinded, placebo-controlled crossover study. Sixteen eyes of 16 patients with central serous chorioretinopathy and persistent subretinal fluid (SRF) for at least 3 months were enrolled. Patients were randomized to receive either spironolactone 50 mg or placebo once a day for 30 days, followed by a washout period of 1 week and then crossed over to either placebo or spironolactone for another 30 days. The primary outcome measure was the changes from baseline in SRF thickness at the apex of the serous retinal detachment. Secondary outcomes included subfoveal choroidal thickness and the ETDRS best-corrected visual acuity.
RESULTS: The mean duration of central serous chorioretinopathy before enrollment in study eyes was 10 ± 16.9 months. Crossover data analysis showed a statistically significant reduction in SRF in spironolactone treated eyes as compared with the same eyes under placebo (P = 0.04). Secondary analysis on the first period (Day 0-Day 30) showed a significant reduction in subfoveal choroidal thickness in treated eyes as compared with placebo (P = 0.02). No significant changes were observed in the best-corrected visual acuity. There were no complications related to treatment observed.
CONCLUSION: In eyes with persistent SRF due to central serous chorioretinopathy, spironolactone significantly reduced both the SRF and the subfoveal choroidal thickness as compared with placebo.
Mots-clé
Adult, Aged, Central Serous Chorioretinopathy/drug therapy, Central Serous Chorioretinopathy/metabolism, Cross-Over Studies, Double-Blind Method, Female, Humans, Male, Middle Aged, Mineralocorticoid Receptor Antagonists/therapeutic use, Prospective Studies, Spironolactone/therapeutic use, Subretinal Fluid/metabolism, Tomography, Optical Coherence, Visual Acuity, Young Adult
Pubmed
Web of science
Création de la notice
01/06/2015 9:09
Dernière modification de la notice
20/08/2019 13:15
Données d'usage